Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H31F3NO6P |
| Molecular Weight | 457.4215 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCOC1=C(C=C(CCC(N)(CO)COP(O)(O)=O)C=C1)C(F)(F)F
InChI
InChIKey=OFRUGVQKZMGHHH-UHFFFAOYSA-N
InChI=1S/C19H31F3NO6P/c1-2-3-4-5-6-11-28-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-29-30(25,26)27/h7-8,12,24H,2-6,9-11,13-14,23H2,1H3,(H2,25,26,27)
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. | 2017 Jan |
|
| Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis. | 2017 Mar |
|
| Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects. | 2017 May |
|
| Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. | 2018 Oct |
Patents
Sample Use Guides
A total of 81 healthy subjects aged 18-55 years were equally randomized to receive amiselimod 0.4 mg, amiselimod 0.8 mg, placebo or fingolimod 0.5 mg once daily for 28 days.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23581980
Created by
admin on Sat Dec 16 19:48:36 GMT 2023 , Edited by admin on Sat Dec 16 19:48:36 GMT 2023
|
PRIMARY | |||
|
QL6WNR6C4D
Created by
admin on Sat Dec 16 19:48:36 GMT 2023 , Edited by admin on Sat Dec 16 19:48:36 GMT 2023
|
PRIMARY | |||
|
942398-85-8
Created by
admin on Sat Dec 16 19:48:36 GMT 2023 , Edited by admin on Sat Dec 16 19:48:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
